METABOLIC SYNDROME PREDICTION METHOD AND DEVICE USING POMC GENE

• SphereGeneric Markers

• 

Summary

The objectives of this license were to compare early predictive marker of the metabolic syndrome with proopiomelanocortin (POMC) methylation status and to determine the association among birth weight, ponderal index, and cord blood methylation status. We collected pregnancy outcome data from pregnant women, cord blood samples at delivery, and blood from children. POMC methylation was assessed by pyrosequencing. We divided subjects into three groups according to cord blood POMC methylation: the low methylation (<10th percentile), mid-methylation, and high methylation (>90th percentile) groups. High POMC methylation in cord blood was associated with lower birth weight, and children with high POMC methylation in cord blood showed higher triglycerides and higher insulin concentrations in blood. Thus, POMC methylation status in cord blood could be an early predictive marker of future metabolic syndrome.

Remarkable

This license has the strength of including human cord blood, which is a material of considerable value that is not readily obtained, and DNA methylation data, which are costly to obtain but of great value. POMC methylation, assessed using cord blood, could be an early predictor of metabolic syndrome.

Contact Point

List